Allogene Therapeutics (ALLO) Long-Term Investments (2018 - 2025)

Allogene Therapeutics has disclosed Long-Term Investments across 8 years of filings, most recently posting $8.0 million for Q4 2025.

• Long-Term Investments for Q4 2025 came in at $8.0 million, down 90.03% year-over-year; the trailing twelve-month figure through Dec 2025 was $8.0 million (down 90.03% YoY), and the FY2025 annual result was $8.0 million, down 90.03% from the prior year.
• Long-Term Investments came in at $8.0 million for Q4 2025 at Allogene Therapeutics, down from $24.9 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $352.2 million in Q4 2021 to a low of $1.1 million in Q2 2024.
• The 5-year median for Long-Term Investments is $26.3 million (2022), against an average of $56.9 million.
• Across the five-year window, Long-Term Investments jumped 9321.59% in 2021 and tumbled 95.08% in 2022, its largest moves.
• Allogene Therapeutics' Long-Term Investments stood at $352.2 million in 2021, then sank by 95.08% to $17.3 million in 2022, then soared by 85.77% to $32.2 million in 2023, then jumped by 150.77% to $80.7 million in 2024, then plunged by 90.03% to $8.0 million in 2025.
• The last three Long-Term Investments figures came in at $8.0 million (Q4 2025), $24.9 million (Q3 2025), and $29.5 million (Q2 2025), per Business Quant data.